Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Are Biomarkers Expression And Clinical-pathological Factors Predictive Markers Of The Efficacy Of Neoadjuvant Chemotherapy For Locally Advanced Cervical Cancer?

Home
Are Biomarkers Expression And Clinical-pathological Factors Predictive Markers Of The Efficacy Of Neoadjuvant Chemotherapy For Locally Advanced Cervical Cancer?

Related Experiment Video

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Are biomarkers expression and clinical-pathological factors predictive markers of the efficacy of neoadjuvant

Antonino Ditto¹, Mariangela Longo¹, Giulia Chiarello¹

¹Gynecological Oncology Department, Fondazione IRCCS Istituto Dei Tumori, Milan, Italy.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

|March 30, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Keywords:

Cervical cancer LACC Locally advanced cervical cancer NACT Neoadjuvant chemotherapy

More Related Videos

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Experiment Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Clinical factors like age, BMI, and grade predict neoadjuvant chemotherapy (NACT) response in locally advanced cervical cancer (LACC). Biomarkers p53, Bcl1, and Bcl2 showed limited predictive value for NACT outcomes.

Area of Science:

Oncology
Gynecologic Oncology
Chemotherapy Research

Background:

Locally advanced cervical cancer (LACC) requires effective treatment strategies.
Neoadjuvant chemotherapy (NACT) is a key therapeutic approach for LACC.
Predicting response to NACT is crucial for optimizing patient outcomes.

Purpose of the Study:

To develop a prediction model for NACT response in LACC using clinical-pathological factors and biomarkers.
To evaluate the prognostic significance of NACT in LACC patients.
To identify reliable predictors of treatment response.

Main Methods:

Retrospective analysis of 88 LACC patients undergoing NACT and surgery.
Evaluation of clinical-pathological data and biomarkers (p53, Bcl1, Bcl2) before and after NACT.

Application of machine learning algorithms (random forest, tree-based boosting, logistic regression) to identify predictors.

Main Results:

Clinical factors, particularly age, BMI, and grade, were significant predictors of NACT response.
p53 showed a moderate association with NACT response, while Bcl1 and Bcl2 were not predictive.
Logistic regression identified grade as the sole significant predictor of response.

Conclusions:

A combined model including clinical factors and p53 did not reliably predict NACT response.
NACT is a safe and effective treatment for chemosensitive LACC patients, potentially avoiding chemoradiotherapy side effects.